The forecast for antihypertensive medicine sales in Germany from 2024 to 2028 shows a steady increase with values remaining relatively stable at $4.3 USD per capita from 2024 to 2026, followed by a slight rise to $4.4 USD per capita in 2027 and 2028. In 2023, the sales stood at $4.2 USD per capita, indicating a year-on-year variation of approximately 2.4% in 2024 from the prior year. The compounded annual growth rate (CAGR) over the last five years is modest at around 1.1%.
Future trends to watch for include the development of new antihypertensive drugs, potential changes in prescription guidelines, and the broader adoption of preventive healthcare measures. Additionally, economic factors, healthcare policy changes, and demographic shifts such as an aging population could significantly impact the demand for antihypertensive medicines.
